Arcus Biosciences, Inc.
RCUS · XNYSCIK 1724521fmd_1YM8AMKHB04YDH34EFESZGTR01Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | 8 | 15 | 78 | 383 | 112 | 117 | 258 | 247 |
| Provision for credit losses | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 14 | 47 | 50 | 78 | 159 | 257 | 288 | 340 | 448 | 523 |
| Total operating expenses | 18 | 55 | 63 | 104 | 202 | 329 | 392 | 457 | 588 | 633 |
| Operating income | (18) | (53) | (55) | (89) | (124) | 54 | (280) | (340) | (330) | (386) |
| Interest expense | – | – | – | – | – | – | 2 | 2 | 4 | 8 |
| Other non-operating income (expense) | 0 | 0 | 5 | 4 | 1 | 1 | 14 | 39 | 48 | 33 |
| Income before taxes | – | – | – | (85) | (123) | 55 | (266) | (301) | (282) | (353) |
| Income tax expense | – | – | – | – | – | 2 | 1 | 6 | 1 | 0 |
| Net income from continuing operations | – | – | – | – | – | 53 | (267) | (307) | (283) | (353) |
| Net income | (18) | (53) | (50) | (85) | (123) | 53 | (267) | (307) | (283) | (353) |